Physician profile
David King Stephens
NPI 1700973633
$551,242.81
in general payments reported to CMS, 2019-2025
29 companies · $77K in 2025
The $77K reported for 2025 was more than what 98% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99K · 2020: $47K · 2021: $46K · 2022: $55K · 2023: $100K · 2024: $127K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Consulting Fee: $77K · Honoraria: $61K · Travel and Lodging: $45K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,134.00 |
| Consulting Fee | $77,109.00 |
| Honoraria | $60,760.00 |
| Travel and Lodging | $44,631.80 |
| Food and Beverage | $11,723.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $210,092.16 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Sk Life Science, INC. | $87,431.37 | 2020-2025 | Xcopri |
| Neurelis, INC. | $80,382.70 | 2020-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $48,520.23 | 2023-2024 | Fycompa |
| Eisai INC. | $43,586.87 | 2019-2022 | |
| Ceribell, INC. | $30,750.00 | 2023-2024 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Neuropace, INC. | $18,025.36 | 2019-2025 | |
| Greenwich Biosciences, INC. | $8,891.19 | 2019-2021 | |
| Livanova USA, INC. | $7,341.02 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $5,823.70 | 2019-2021 | |
| Shire North American Group INC | $3,230.00 | 2019 | |
| Ucb Sa | $2,700.00 | 2022 | |
| Zimmer Biomet Holdings, INC. | $1,089.30 | 2019 | |
| Ucb Biosciences INC. | $1,050.00 | 2019 | |
| Medtronic, INC. | $806.67 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $806.64 | 2022-2025 | Epidiolex |
| Zoll Medical Corporation | $233.33 | 2019 | |
| Sunovion Pharmaceuticals INC. | $138.26 | 2019 | |
| Medtronic USA, INC. | $63.84 | 2019 | |
| Neurocrine Biosciences, INC. | $54.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.95 | 2019 | |
| Lilly USA, LLC | $45.48 | 2019 | |
| Bausch Health US, LLC | $27.96 | 2019 | |
| Adamas Pharmaceuticals, INC. | $27.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $23.73 | 2019 | |
| Amgen INC. | $22.06 | 2019 | |
| Upsher-Smith Laboratories LLC | $18.63 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.73 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David King Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.